Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2009

Conditions
Coronary Artery Disease
Interventions
GENETIC

intramyocardial injection of VEGF-A165/bFGF:placebo plasmid

The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption

Trial Locations (1)

04-628

Institute of Cardiology, Warsaw

All Listed Sponsors
collaborator

Center of Oncology, Warsaw, Poland

UNKNOWN

collaborator

Medical University of Warsaw

OTHER

collaborator

Ministry of Scientific Research and Information Technology, Poland

OTHER_GOV

collaborator

Polpharma Foundation for Development of Polish Pharmacy and Medicine

UNKNOWN

lead

National Institute of Cardiology, Warsaw, Poland

OTHER

NCT00620217 - Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial | Biotech Hunter | Biotech Hunter